Galsky, M. D., Bellmunt, J., Mantia, C., Garmezy, B., Iyer, G., Petrylak, D. P., Gjini, E., Joshi, A., Mikhailov, Y., Nguyen, A., Kakrecha, B., Meyers, M. L., Bowden, M., Milowsky, M. I., Gao, X. (2026). Updated clinical results and associated biomarkers from an ongoing phase 1 study of FX-909, a first-in-class peroxisome proliferator-activated receptor gamma (PPARG) inhibitor, in patients (pts) with advanced urothelial carcinoma (adv UC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.lba639